Format

Send to

Choose Destination
J Am Coll Cardiol. 2018 May 15;71(19):2079-2088. doi: 10.1016/j.jacc.2018.02.071.

B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure.

Author information

1
Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
2
Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address: d.gupta@vanderbilt.edu.
3
Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Endocrinology, Vanderbilt University School of Medicine, Nashville, Tennessee; Faculty Research Scholars Program, Vanderbilt University School of Medicine, Nashville, Tennessee.
4
Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.

Abstract

BACKGROUND:

Circulating B-type natriuretic peptide (BNP) concentrations strongly predict mortality in patients with heart failure (HF). Both cardiac and extracardiac stimuli influence BNP levels, suggesting that BNP might have similar prognostic value in patients without HF.

OBJECTIVES:

The aim of this study was to compare the prognostic value of BNP between patients with and those without HF.

METHODS:

Using the Vanderbilt University Medical Center electronic health record, 30,487 patients (median age 63 years, 50% men, 17% black, 38% with HF) who had a first plasma BNP measurement between 2002 and 2013, with follow-up through 2015, were studied. The risk for death according to BNP level was quantified using multivariate Cox proportional hazards models.

RESULTS:

BNP levels were lower in patients without HF (median 89 pg/ml; interquartile range: 34 to 238 pg/ml) compared with those with HF (median 388 pg/ml; interquartile range: 150 to 940 pg/ml) (p < 0.0001). Over 90,898 person-years of follow-up, 5,903 patients without HF (31%) and 6,181 patients with HF (53%) died. In multivariate models including demographic and clinical characteristics, BNP and age were the strongest predictors of death in both patients with and those without HF. In acute care settings and even among outpatients with modestly elevated BNP, the risk for death according to BNP was similar between patients with and those without HF. For instance, a BNP level of 400 pg/ml was associated with a 3-year risk for death of 21% (95% confidence interval: 20% to 23%) and 19% (95% confidence interval: 17% to 20%) in patients with and those without HF, respectively.

CONCLUSIONS:

Among patients without HF, plasma BNP level is a stronger predictor of death than traditional risk factors. The risk for death associated with any given BNP level is similar between patients with and those without HF, particularly in the acute care setting.

KEYWORDS:

death; electronic health record; prognosis; retrospective

PMID:
29747827
PMCID:
PMC5951190
[Available on 2019-05-15]
DOI:
10.1016/j.jacc.2018.02.071

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center